Hedge Fund Database
The curated database of hedge funds that publish investor letters. Research by geography, strategy, and schools of thought.
| # | Fund | Strategy | Style | Geography | AUM | Latest Letter |
|---|---|---|---|---|---|---|
The curated database of hedge funds that publish investor letters. Research by geography, strategy, and schools of thought.
| # | Fund | Strategy | Style | Geography | AUM | Latest Letter |
|---|---|---|---|---|---|---|
As of Oct 14, 2026
Parnassus Growth Equity Fund (Investor Shares) posted a net return of 4.44% in the third quarter of 2026, significantly outperforming the Russell 1000 Growth Index benchmark return of 0.92%. For the year-to-date period, the strategy delivered a net return of 10.88% against 6.30% for the benchmark index. Relative outperformance was primarily driven by stock selection in Health Care and Information Technology, partially offset by an underweight posture in Energy and holdings in Materials. The strategy closed the quarter with an active underweight in Information Technology (46.3% of total net assets versus 56.5% for the benchmark), active overweights in Health Care (13.0% vs. 5.4%), Materials, and Financials, zero allocation to Energy, Real Estate, or Utilities, and a cash reserve of 0.4%. The investment team operates against a macroeconomic regime characterized by persistent inflation, elevated interest rates following Federal Reserve monetary tightening, geopolitical friction from the Iran conflict disrupting global energy supplies, and shifting trade tariff policies. While acknowledging that short-term equity markets have been driven by narrative-fueled momentum rather than fundamentals—punishing earnings misses and software business models vulnerable to artificial intelligence disruption—the managers maintain that structural enterprise investment in artificial intelligence compute and cross-sector productivity gains will support durable equity appreciation. Portfolio activity was exceptionally restrained during the quarter, with zero position initiations or complete exits executed, other than the immediate liquidation of shares received from the Mobility Global spin-off via S&P Global. Capital allocation remained anchored in high-conviction holdings across healthcare technology leaders such as Twist Bioscience and Natera, alongside infrastructure bottleneck providers including GE Vernova and Comfort Systems USA. Top portfolio weightings remain anchored by mega-cap technology leaders NVIDIA (11.3%), Alphabet (10.5%), and Meta Platforms (4.9%).
The strategy pursues strong long-term returns by owning a concentrated portfolio of innovative, high-quality U.S. large cap companies that are well positioned to benefit from long-term secular trends.
The investment team maintains cautious optimism amid an intensifying set of macroeconomic crosscurrents, asserting that the structural foundation for equity appreciation remains solid due to the multiyear artificial intelligence investment cycle, cross-industry productivity innovations, and a resilient underlying economy. While acknowledging that headline risks from interest rates, inflation, and geopolitical turmoil have made market reactions unforgiving, the managers plan to remain nimble and leverage volatility to selectively establish positions in companies possessing durable moats, pricing power, and expanding end markets.
Moderate Conviction Bullish
Market Conviction
Growth Outlook
Risk Appetite
Capital Deployment
Forward Guidance
Language Signal
Perceived Risk
Opportunity Density
Time Horizon
Top Conviction Themes
Key Catalysts
Every insight in this database connects to the original source. Read the actual thesis, see the actual concerns, and make your own call.
Buyside Digest has no business relationship, partnership, agency, sponsorship, endorsement, or affiliation with Parnassus Growth Equity Fund or any other manager whose content appears on the Service, except where expressly stated. We do not receive Manager Content directly from managers in most cases; content is collected from publicly available sources. Managers have not necessarily reviewed, approved, authorized, or endorsed our display of their content, our editorial commentary, our metadata extraction, or our classifications. Use of a manager’s name is for accurate attribution and identification purposes only, under principles of nominative fair use.
Buyside Digest does not independently verify the regulatory status, registrations, licensing, qualifications, credentials, or professional standing of managers whose content appears on the Service. We do not represent that managers are properly registered with applicable regulatory bodies, that their content complies with applicable securities laws, or that their performance representations are accurate. Inclusion of a manager in our database is based on the publicly available nature of their content, not on our verification of their regulatory status or content compliance. Users are responsible for conducting their own due diligence on any manager.
Performance data, returns, assets under management (“AUM”), and similar figures displayed on this page are sourced from publicly available manager communications (including investor letters), public filings, or other third-party sources. Buyside Digest does not independently verify performance figures, calculate returns, or audit manager-reported data. Such figures: May be selectively reported by the manager; May use non-standard calculation methodologies; May not reflect fees, expenses, taxes, or other costs; May be inconsistent across reporting periods; May be outdated. Past performance is not indicative of future results. Performance figures should not be relied upon for investment decisions without independent verification. Users should request audited performance data directly from the manager and conduct their own due diligence.